1 – 12 of 12
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
A randomized controlled trial to isolate the effects of fasting and energy restriction on weight loss and metabolic health in lean adults
(
- Contribution to journal › Article
- 2020
-
Mark
Epigenetic markers associated with metformin response and intolerance in drug-naïve patients with type 2 diabetes
(
- Contribution to journal › Article
- 2019
-
Mark
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma
(
- Contribution to journal › Article
-
Mark
Treating murine inflammatory diseases with an anti-erythrocyte antibody
(
- Contribution to journal › Article
-
Mark
The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk
(
- Contribution to journal › Article
- 2018
-
Mark
Human thymopoiesis is influenced by a common genetic variant within the TCRA-TCRD locus
(
- Contribution to journal › Article
-
Mark
The vermiform appendix impacts the risk of developing Parkinson’s disease
(
- Contribution to journal › Article
- 2017
-
Mark
Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes
(
- Contribution to journal › Article
- 2016
-
Mark
IRF7 inhibition prevents destructive innate immunity-A target for nonantibiotic therapy of bacterial infections
(
- Contribution to journal › Article
-
Mark
Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis
(
- Contribution to journal › Article
-
Mark
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
(
- Contribution to journal › Article
- 2015
-
Mark
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
(
- Contribution to journal › Article